Applications of Acrivastine in Industrial Manufacturing

Acrivastine serves a highly specialized role in the pharmaceutical manufacturing sector, where purity, traceability, and process consistency are essential. As an established second-generation antihistamine active ingredient, its primary uses remain focused in regulated downstream production of oral solid, liquid, and combination medicinal products. The following application scenarios provide a detailed description of real-world industry practices for integrating this compound into advanced dosage forms.

1. Antiallergic Oral Tablets Production

Pharmaceutical manufacturers select acrivastine for the formulation of modern non-sedating antihistamine tablets, prioritizing rapid absorption and patient compliance. This material is introduced during the active blending phase before granulation, enabling direct tableting or further processing through wet or dry granulation as required for batch-specific flow properties. Producers further control particle size and blend uniformity to maintain dose uniformity, as demanded by global regulatory authorities. Finished tablets undergo comprehensive chemical, physical, and dissolution analysis before packaging.

Industry compliance standards

• United States Pharmacopeia (USP Monograph for Acrivastine)
• European Pharmacopoeia (Ph. Eur. 10.0)
• ICH Q7 GMP for Active Pharmaceutical Ingredients
• 21 CFR Part 211 Good Manufacturing Practice for Finished Pharmaceuticals

Typical usage ratio

• Standard tablet formulations use 4–8 mg acrivastine per dosage unit.
• Active ingredient comprises typically 1–3% of the final blend, adjustable based on tablet weight and potency specifications in various target markets.

Downstream process integration

• Direct wet or dry blending of acrivastine API with pharmaceutical excipients in industrial mixers prior to granulation.
• Integration into roller compaction or high-shear granulation lines for mass production batches.

Final product types

• Non-prescription antihistamine tablets under various global brand names
• Generic prescription allergy relief tablets
• Private label oral solid dose allergy products
• Pediatric and adult formulations targeting allergic rhinitis and urticaria symptoms

2. Oral Syrup and Liquid Suspension Formulations

Liquid allergy medications provide a palatable, flexible-dosing option, particularly suited to pediatric, geriatric, and dysphagia patients. Manufacturers utilize acrivastine as a micronized API for inclusion in sugar-based syrups or oral suspensions. The process requires tight control of pH, solubilizers, preservatives, and viscosity agents for physical and chemical API stability throughout the stated shelf-life, guided by ICH stability protocols. Quality control verifies uniform dispersion, content uniformity, and absence of particulates across each production lot.

Industry compliance standards

• British Pharmacopoeia (BP) requirements for oral solutions/suspensions
• ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances
• FDA cGMP for Liquid Pharmaceuticals (21 CFR Parts 210, 211)
• WHO Prequalification Guidelines for Finished Dosage Forms

Typical usage ratio

• Contains between 0.5–1.5 mg/ml acrivastine, accurately dosed based on patient age and target bottle size.
• Final API content may represent 0.1–0.6% of total formulation mass, adjusted for solubility and viscosity management.

Downstream process integration

• Introduction after initial aqueous base preparation, followed by homogenization to ensure fine particle size distribution.
• Stabilizer and preservative addition prior to final filtration and aseptic bottle filling.

Final product types

• Pediatric oral antihistamine suspensions targeting seasonal allergies
• Adult allergy relief syrups for over-the-counter distribution
• Liquid combination antihistamine-cough/cold medicines where legal and clinically justified
• Sugar-free, dye-free liquid formulations for specialty markets

3. Fixed-Dose Combination Allergy Capsule Manufacturing

Combination dosage forms, pairing acrivastine with other anti-allergy or decongestant actives, require high-precision batch compounding and stringent segregation procedures to avoid cross-contamination. The integration of acrivastine occurs at the powder micro-blend stage, using validated blending and in-line content uniformity testing. Automated capsule filling machinery meters the blended powder into hard gelatin or HPMC capsules, with in-process control checks ensuring each unit contains the correct ratio of all actives before closure and blister packaging.

Industry compliance standards

• EMA Guideline on Fixed Combination Medicinal Products
• Japanese Pharmacopoeia (JP) standards for capsule dosage forms
• ICH Q8 Pharmaceutical Development
• ISO 15378:2017 for Primary Packaging Materials

Typical usage ratio

• Each capsule contains 8 mg acrivastine with complementary dosages of pseudoephedrine (60 mg typical in some combinations).
• The acrivastine portion commonly represents 1–2% of total capsule powder mass, finalized per regulatory monograph limits in each country.

Downstream process integration

• Dry powder micro-blending under HEPA-filtered environments; real-time blending profile adjustments based on assay feedback.
• Direct powder filling into capsules using continuous motion filling equipment and on-line weight verification.

Final product types

• Fixed-dose allergy and sinus relief capsules for pharmacy sales
• Dual-action OTC allergy/decongestant hard capsule medications
• Internationally exported generics matching innovator formulations
• Prescription combination antihistamine products across regulated markets

4. Development of Antihistamine Orally Disintegrating Films (ODF)

Rapidly dissolving oral film technology offers improved patient convenience and dose flexibility, particularly for individuals with swallowing difficulties. In ODF manufacturing, acrivastine is solubilized or suspended within a hydrocolloid matrix, blended with film-forming polymers, plasticizers, and flavor masking agents, then cast as uniform sheets using continuous-film extrusion or solvent-casting processes. Finished films are cut, individually packaged to prevent moisture ingress, and verified for thickness, uniformity, and rapid dissolution.

Industry compliance standards

• USP <2040> Disintegration and Dissolution of Dietary Supplements
• FDA Guidance for Industry: Orally Disintegrating Tablets and Films
• ICH Q3A (R2) Impurities in New Drug Substances
• ISO 14644 Cleanroom Standards for Exposed Film Processing

Typical usage ratio

• Each ODF strip delivers 4–8 mg acrivastine per film.
• The film matrix composition results in 0.8–1.2% API by weight, optimized for film strength, palatability, and speed of dissolution.

Downstream process integration

• Direct API addition into aqueous or hydroalcoholic film-casting blends under controlled humidity to prevent crystallization.
• Formulated blend deposited onto continuous casting beds or rotary drum extruders, followed by precision drying and slitting.

Final product types

• Unit-dose orally disintegrating anti-allergy films
• Pediatric-friendly fast-melt oral strips for allergy management
• Travel and single-use dosage forms compliant with diverse packaging requirements

5. Active Reference Standard Preparation for Analytical Laboratories

Pharmaceutical quality control and regulatory compliance laboratories prepare certified reference standards using high-purity acrivastine to validate, calibrate, and maintain USP/Ph. Eur.-specified analytical methods. These analytical standards underpin the release, stability testing, and batch homogeneity assessment for finished dose forms. Full traceability and COA verification are mandated, with precise weighing, dissolution, and aliquoting under controlled conditions integral to reproducibility across global laboratory networks.

Industry compliance standards

• Pharmacopoeial standards including USP RS, Ph. Eur. CRS
• ISO 17034 General Requirements for the Competence of Reference Material Producers
• ICH Q2 (R1) Validation of Analytical Procedures
• WHO Guidelines on the Preparation, Characterization, and Establishment of International and Other Biological Reference Standards (TRS 1003)

Typical usage ratio

• Reference standard stock solutions typically prepared at 0.1–1.0 mg/ml for HPLC, UV, and MS calibration, precise concentration chosen per compendial method.
• Reference substance aliquots range from 5–100 mg, prepared in single-use or batch vials for inter-laboratory consistency.

Downstream process integration

• Primary weighing and dissolution of API directly within controlled-environment analytical labs.
• Bottling, labeling, and distribution under validated conditions to downstream QC and development teams, with retesting per stability protocol.

Final product types

• Official compendial reference standards for regulatory submissions
• Secondary certified reference materials for routine QC and method validation
• Calibration kits for pharmaceutical company global laboratory networks